IL-15RαFc superagonist SHR-1501 with or without bacille Calmette Guerin (BCG) for high-risk non-muscle invasive bladder cancer (NMIBC): A phase 1/2 study. RFS rate in all Pts, % ( 95%CI) 96 (88, 100) ...
Anktiva plus BCG aims to treat BCG-unresponsive NMIBC with papillary disease, potentially reducing radical cystectomy need. The treatment showed high rates of surgery avoidance and disease-free ...
More than three decades ago, the U.S. Food and Drug Administration (FDA) approved Bacillus Calmette-Guérin (BCG) as the first immunotherapy against cancer. And it is still used today to treat ...
Tokyo BCG is not inferior to TICE, and may help ease the BCG shortage. For treatment of high-grade (HG) non-muscle invasive bladder cancer (NMIBC), the Bacillus Calmette-Guérin (BCG) strain Tokyo-172 ...
rBCG offers an alternative to TICE® BCG amid U.S. shortages, impacting bladder cancer treatment availability. FDA's Expanded Access Program allows investigational rBCG use when no satisfactory ...
In a recent study posted to the bioRxiv* preprint server, researchers assessed the impact of Bacillus Calmette-Guérin (BCG) vaccination on the protection provided by severe acute respiratory syndrome ...
Immunocompromised patients with bladder had a higher risk of disease progression and recurrence when compared to their non-immunocompromised counterparts. Immunocompromised patients with bladder ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results